Support Us  Blog Contact Us עברית
The Jerusalem Institute for Israel Studies
Home    News & Events   JIIS Bulletin- September 2014
News & Events
News Database
June 2018 - Forever in Our Hearts?
May 2018 - The American Embassy's transfer to Jerusalem
April 2018 - Upcoming events
September 2017 - Happy New Jewish Year
August 2017 - 'Residents, Not Citizens'
April 2017 - Making space for each other
April 2017 - Happy Passover
December 2016 - Employment and Livelihood among Hared and Ba’alei Teshuva
November 2016 - Together or to each his own?
September 2016 - Updates and upcoming events
June 2016 - The Statstical Yearbook of Jerusalem
April 2016 - The Divine Commander
February 2016 - Upcoming events
December 2015 - Upcoming events
September 2015 - Upcoming events
September 2015 - Shana Tova
June 2015 - East and West: Equality and Inequality in Jerusalem
JIIS Bulletin - June 2015
JIIS Bulletin- September 2014
JIIS Bulletin - July 2014
JIIS Bulletin - March 2014
JIIS Bulletin - September 2013
JIIS Bulletin-Statistical Yearbook
JIIS Bulletin - May 2013
JIIS Bulletin-Remembering Barsi
JIIS Bulletin - December 2012
JIIS Bulletin - September 2012
JIIS Bulletin - July 2012
JIIS Bulletin - May 2012
JIIS Bulletin - April 2012
JIIS Bulletin - February 2012
JIIS Bulletin - December 2011
JIIS Bulletin - September 2011
JIIS Bulletin - July 2011
JIIS Bulletin - June 2011
JIIS Bulletin - March 2011
JIIS Bulletin - January 2011
JIIS Bulletin - November 2010
JIIS Bulletin - October 2010
JIIS Bulletin- September 2014
Following Jerusalem's biotechnology industry
Jerusalem has a real advantage when it comes to the current efforts to develop the local biotechnology industry: it has top hospitals, excellent academic infrastructures, significant local industries, and a ready labor force. This advantage is reflected in the number of people employed and the large number of biotech companies found in Jerusalem.  

So it was natural that the biotechnology be included in the government's five-year Marom Plan to boost development and the economy in Jerusalem. In fact, one of the stated main goals of Marom is to strengthen the city as a focus of research, development and industry in the realm of biotechnology. To that end, the Jerusalem Development Authority (JDA) established the BioJerusalem Center, to encourage the local industry via grants and benefits. In this framework, JIIS, which is assisting the JDA by monitoring and evaluating progress in the Marom Plan, is also assessing the contribution of the practical tools offered by BioJerusalem. The Institute maps activities, assists in the development of strategies for action in the field, monitors and conducts periodic evaluations.

In the first reports (in Hebrew) on the subject (one describing the indicators devised to monitor the biotech industry and the other assessing the policy tools that exist in this area), researchers Dr. Dan Kaufmann and Yamit Naftali offer the following findings: 

- The benefits package offered by BioJerusalem plays an important role in companies' decisions to set up in the city or, if that is where they began, to remain. In other words, they appreciate those benefits and it facilitates their work.
- However, most of the companies surveyed learned about the benefits by chance, for example, at a conference or by word of mouth. This suggests that the might be a marketing glitch that, if rectified, could open Jerusalem to more biotech companies. 
- Similarly, some companies think the benefits are only available for workers who live in Jerusalem, which is not the case.

In 2010-13, 23 companies received a benefit package from the JDA, totaling NIS 8.9 million, and 192 workers received employment grants.

In all, they add, 11.1% of the biotech companies in Israel are located in Jerusalem, compared to only 9.7% in the cities Rehovot and Nes Ziona, and 33% in the central region. In 2012-13, the number of such companies grew by about 5% in Jerusalem, reaching 117 at the present time. Most of them are small firms, with anywhere between 1 and 20 employees, which explains why the total number of people employed in the industry in Jerusalem is only 9% of the total number of biotech employees in Israel. 

The indicators presented in the report emphasize numerous strengths that are found in Jerusalem that give the city a significantly competitive edge in the development of the biotech industry in Israel. They also highlight the fact that the industry is in a period of growth. 

Kaufmann and Naftali note that 2013 marked the first year that the indicators were applied; previously comparisons were made, but relevant data were not always available. Also, the Marom Plan was only launched in 2012, so current policy was applied from then. Therefore, it is still hard to fully assess the influence of the updated policy on the industry. This is likely to change as the five-year plan moves forward. 

Previous Next
Advanced Search
© All rights reserved to The Jerusalem Institute for Israel Studies Privacy Policy Consulting by בניית אתרים ICS